Triple therapy trial aims to ease rare lung disease
NCT ID NCT07266519
First seen Jan 11, 2026 · Last updated May 05, 2026 · Updated 20 times
Summary
This study tests whether a combination of three drugs (an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, and sotatercept) can improve blood flow in the lungs of people newly diagnosed with pulmonary arterial hypertension (PAH). 25 adults aged 18-70 will receive the triple therapy for 24 weeks. The main goal is to see if it lowers pressure in the lung arteries. After the study, doctors will decide ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.